If you’re using Mounjaro (tirzepatide) for weight management under UK/NHS-style frameworks, you’ll see one rule repeated everywhere:

If you lose less than 5% of your starting weight after 6 months on your highest tolerated dose, it becomes a decision point about whether to continue.

This is not meant to shame you or force a one-size-fits-all stop. It exists because at very low response, the risks and burden of treatment can outweigh the benefits, and services need a structured way to decide what happens next.

For the full policy background, eligibility context, and rollout details, see:
NICE guidance for Mounjaro weight loss (TA1026)

For the full product overview (how it’s used, dosing, and expectations), keep this open:
Mounjaro weight loss injection pen

Table of Contents

The rule in one sentence (what NICE actually says)

In NICE TA1026 recommendations:

“If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue treatment, taking into account the benefits and risks of treatment for the person.”

So it’s a review decision, not an automatic switch-off.

NICE’s practical prescribing guide reinforces the same logic and adds an important interpretation:

If someone lost less than 5% after 6 months on the highest tolerated dose, “the risks of treatment are likely to outweigh any benefits” (and the person’s engagement with lifestyle measures should be considered).

What “6 months on the highest tolerated dose” means

This is where people get confused.

Highest tolerated dose ≠ “the highest dose on the pen”

It means the highest weekly dose you can take consistently without side effects that are unacceptable for you.

NICE’s practical guide states:

If adverse effects happen during titration, don’t increase until they resolve or become tolerable; if they don’t resolve, consider titrating down by 2.5 mg.

So “highest tolerated dose” might be your target dose, or it might be lower based on tolerability.

When does the 6-month clock start?

NICE TA1026 phrases it as “after 6 months on the highest tolerated dose.”

Practical meaning:

If you’re still titrating and not yet stable on your highest tolerable dose, you’re not really at the cleanest point to judge the rule.
The fairest way to apply the rule is: once you reach and maintain your highest tolerated dose, then you evaluate the weight response over a meaningful period on that dose.

(Services may operationalise this slightly differently, but the wording is clear: it’s about time on the highest tolerated dose.)

How to calculate “5% weight loss” (simple and fast)

Formula

5% target loss = starting weight × 0.05

Examples table (so you can self-check in seconds)

Starting weight	5% target loss
80 kg	4.0 kg
90 kg	4.5 kg
100 kg	5.0 kg
110 kg	5.5 kg
120 kg	6.0 kg

So if you started at 110 kg, you’re aiming for at least 5.5 kg down by the review point.

What to do at the 6-month review (decision framework)

If your weight loss is ≥5%
That usually supports continuing (subject to tolerability and overall benefit/risk), because you’ve demonstrated meaningful response.

If your weight loss is <5%
Don’t jump straight to “it failed.” Use this structured review:

Step 1: Confirm it’s a fair measurement

Use a baseline weight recorded at start.
Use a recent weight taken consistently (similar time of day, similar clothing).
Look at weekly averages, not a single weigh-in (water swings can hide progress).

Step 2: Confirm you were truly on the highest tolerated dose

Were you stable on the dose?
Were side effects limiting you?
Were you delaying titration increases repeatedly because symptoms weren’t tolerable?

If you weren’t stable on your highest tolerated dose, the “6 months on the dose” evaluation may not yet be meaningful.

Step 3: Check adherence (the silent reason for non-response)

Missed injections (travel, supply, forgetting)
Long gaps between doses
Stopping and restarting

Even “small inconsistency” can flatten outcomes.

Step 4: Check the most common “hidden blockers”

These aren’t moral failures they’re pattern issues:

Liquid calories (sweet coffees, juices, alcohol)
Weekend eating cancelling weekday deficit
Constipation masking scale change
Sleep/stress increasing cravings
Other medicines that increase appetite/weight

Step 5: Make the NICE-style decision (benefits vs risks)

At this point you’re aligned with NICE language:

TA1026: decide whether to continue based on benefits and risks.
NICE practical guide: if <5% after 6 months on highest tolerated dose, risks are likely to outweigh benefits, and engagement with lifestyle measures matters.

That usually leads to one of three outcomes:

Outcome A: Continue (exceptional/individualised)

This would typically need a clear reason why continuing is justified despite low weight response (for example, meaningful other benefits, or the review period wasn’t a fair test because dose wasn’t stable).

Outcome B: Stop and escalate support

This is the common path if response is low and side effects/burden are not worth it.

Outcome C: Refer / change the support level

NICE’s practical guide explicitly mentions considering referral to specialist services or alternative management pathways when response/tolerability is an issue.

Decision table: “<5% at 6 months” – what to check and what to do

If you’re <5%…	Check this first	Then decide
You were not stable on the highest tolerated dose	Titration delays, dose reductions, side effects	Extend review once stable
You missed doses	Adherence gaps	Rebuild weekly consistency
You were consistent but diet structure was weak	Liquid calories/weekends	Tighten routines + re-check
You were consistent and structured	True low response	Benefit/risk decision (often stop)

A clinician discussion script (so you don’t get brushed off)

Use this in your review:

“I understand NICE TA1026 says if I’m under 5% after 6 months on my highest tolerated dose, we should decide whether to continue based on benefits and risks. Can we confirm (1) my baseline weight, (2) when I reached my highest tolerated dose, and (3) whether my last 6 months were truly on that dose? Then can we decide the best next step continue, stop, or change support level?”

Key takeaway

The “5% at 6 months” rule is not a punishment it’s a structured clinical decision point:

NICE TA1026 tells clinicians to decide whether to continue if you’re <5% after 6 months on highest tolerated dose, based on benefits vs risks.
NICE’s practical guide adds: at that rate of loss, risks are likely to outweigh benefits, and lifestyle engagement matters.

And that’s exactly how your page should guide users: calculate → verify dose/time → diagnose blockers → make the decision.